New study suggests Avandia (Glaxo Smith Kline) offers no increased risk of Heart Attack in patients with Type 2 Diabetes

An FDA re-adjudication of the RECORD trial of Avandia (rosiglitazone), from Glaxo Smith Kline, in patients with Type 2 Diabetes has confirmed the findings of the original trial, suggesting that Avandia doesn't increase cardiovascular risk.

Concerns over the drug began in 2007 when results of a meta-analysis suggested that patients taking it could be at increased risk of a heart attack. Avandia was withdrawn from the market in the EU and its use severely restricted in the US in 2010. The new results will be discussed at an FDA advisory committee meeting in early June.